Chronic myeloid leukemia CD34 þ cells have elevated levels of phosphatidylinositol 3,4,5 trisphosphate (PtdIns(3,4,5)P 3 ) and lack a PtdIns(3,4,5)P 3 response to cytokines and chemotactic factors; effects reversed by imatinib Leukemia (2005) The pivotal role of phosphatidylinositol 3 kinase (PI3K) in signalling for the survival, proliferation and differentiation of normal hematopoietic progenitor cells is now clear. In fact, mice which do not express the hematopoietic-specific SH2-containing inositol 5 phosphatase establish a fundamental role for regulation of PtdIns(3,4,5)P 3 metabolism in myelopoiesis in that they suffer from a myeloproliferative disorder. 1 Chronic myeloid leukaemia (CML) is a myeloproliferative disorder associated with the expression of the BCR/ABL protein tyrosine kinase. BCR/ABL activates PI3K and this pathway has been shown to have an important role in BCR/ABL-mediated leukemogenesis. 2 Hematological remission in CML patients can be achieved with imatinib, a competitive inhibitor of BCR/ABL kinase. Clinical use of imatinib is associated in some cases with the emergence of drug resistance; thus, patients may benefit from combined drug therapies. 2 Since PI3K is such a target, a clearer understanding of PtdIns(3,4,5)P 3 metabolism in CML progenitor cells is required. We have established an assay for PtdIns(3,4,5)P 3 where cell numbers are limited 3 and show that compared to normal progenitor cells CML cells have markedly elevated PtdIns(3,4,5)P 3 levels. This is reduced by imatinib and, importantly, the cells subsequently respond to growth factors and chemokinetic factors with an increase in PtdIns(3,4,5)P 3 level, as do normal cells.
The level of PtdIns(3,4,5)P 3 in CD34 þ cells was determined using the fluorescent PtdIns(3,4,5)P 3 -binding protein probe (GFP GRP-1 PH) and the control with a point mutant that has no PtdIns(3,4,5)P 3 binding activity (GFP K273AGRP-1 PH), a method that has yielded quantitative information on the levels of PtdIns(3,4,5)P 3 in adherent cells. 4 Our modifications make it suitable for screening hematopoietic stem and progenitor cells. 3 GFP GRP-1 PH binding (Figure 1a ) in CML CD34 þ cells was 10.370.2 times higher than normal CD34 þ cells (n ¼ 3, mean7s.e.m.). Inhibition of PI3K for a short period with LY294002 (50 mM) gave a substantial (eight-fold) decrease in binding of GFP GRP-1 PH (Figure 1a) . Similarly, preincubation of CML CD34 þ cells for 16 h with imatinib (1 mM) decreased the GFP GRP-1 PH binding by 7.3-fold (Figure 1c ). Neither LY294002 nor imatinib had an effect on GFP K273AGRP-1 PH binding. We conclude that PI3K activation is at least in part essential for the elevated PtdIns (3,4,5)P 3 levels and is a direct consequence of BCR/ABL activation.
There is an evidence that the CML CD34 þ progenitor cell population undergoes autocrine production of IL-3, G-CSF and SCF leading to proliferation. 5 If this is the case these cytokines may be able to super-stimulate the CML progenitor cell to undergo further elevation in PtdIns(3,4,5)P 3 levels thereby promoting (enhanced) proliferation. We tested this hypothesis by treating CD34 þ CML cells with cytokines (SCF, G-CSF, GM-CSF, IL-3 and all combined) for a period of 10 min. We found that none of the cytokines could significantly elevate the levels of PtdIns (3,4,5)P 3 beyond that of the untreated control cells (Figure 1c ). These data infer that the PI3K pathway is constitutively activated in CML progenitor cells. The lack of effect of cytokines on PtdIns (3,4,5)P 3 in CML progenitor cells could be due to the presence of BCR/ABL activity that renders the cells unable to initiate further PtdIns (3,4,5)P 3 responses. If so, the inhibition of BCR/ABL should render cells competent to respond to external stimuli in the PtdIns(3,4,5)P 3 pathway. We, therefore, assessed the effect of imatinib on the ability of CML CD34 þ cells to respond to cytokines with an increase in PtdIns(3,4,5)P 3 levels (Figure 1b  and 1c) . The cytokines G-CSF, GM-CSF, IL-3 or SCF increased GFP GRP-1 PH binding by 6.1, 7.2, 8.2 and 9.4-fold, respectively, in normal CD34 þ cells (Figure 1b) . The combined cytokines gave GFP GRP-1 PH binding of the same order as seen with each individual cytokine. We surmise that the activation of PI3K under these conditions is near maximal. In no instance did imatinib affect the growth-factor-stimulated increase that was observed. Given the ability of imatinib to decrease PtdIns(3,4,5)P 3 levels in CML CD34 þ cells (Figure 1c) the compound is plainly effective with respect to BCR/ABL in our assays. When CML CD34 þ cells are pretreated with imatinib, the cytokine response is restored (Figure 1c) . The fold increases observed with G-CSF, GM-CSF, IL-3 or SCF were 4.3, 5.3, 6.9, and 8.8, respectively. It is clear from these data that imatinib induces in CML CD34 þ cells the ability to elicit near normal responses to cytokines with respect to PtdIns(3,4,5)P 3 production. The level of PtdIns(3,4,5)P 3 seen in CML CD34 þ cells not treated with imatinib was equivalent to that seen when cytokines were added. We, therefore, conclude that BCR/ABL is maintaining PtdIns(3,4,5)P 3 in CML CD34 þ cells at a level equivalent to that observed in normal cells after cytokine addition.
Growth factors are not the only agonists that can stimulate PtdIns(3,4,5)P 3 production. Recently we showed that murine hematopoietic stem cells respond to the chemotactic factor, SDF-1 and the chemokinetic factor, LPA with elevated PtdIns(3,4,5)P 3 levels. 3, 6 Transcripts for Edg 2, 4 and 7 (LPA receptors) are present on human normal and CML CD34 þ cells (data not shown). LPA, as anticipated therefore, can stimulate an increase of 7.8-fold in GFP GRP-1 PH binding in normal CD34 þ cells (Figure 2a ). Normal CD34 þ cells also displayed a response to SDF-1 (11.7-fold increase in GFP GRP-1 PH binding, Figure 2a) . CML CD34 þ cells are known to have a decreased motile response to SDF-1 and we hypothesized this may be due to a lack of ability to activate PI3K beyond the stimulation level achieved by BCR/ABL. In CML CD34 þ cells, no elevation in GFP GRP-1 PH binding was observed with either SDF-1 or LPA (Figure 2b) . Levels of PtdIns(3,4,5)P 3 in SDF-1-treated and untreated cells were decreased by the addition of LY294002 (data not shown). However, when CML CD34 þ cells were pretreated with imatinib an agonist-mediated elevation in GFP GRP-1 PH binding in response to SDF-1 and LPA was observed (Figure 2b ). This restored ability in imatinib-treated CML cells to generate PtdIns(3,4,5)P 3 in response to these agents leading us to consider whether motile responses were altered by imatinib using transwell migration assays (Figure 3 ). Normal CD34 þ cells exhibited a migratory response to SDF-1 and LPA, and when combined these agents gave an additive response. The addition of imatinib to normal CD34 þ cells had no effect on cell migration. In CML CD34 þ cells, as previously reported, SDF-1 did stimulate migration, but this was diminished compared to normal CD34 þ cells (31% of cells migrated as compared to 16% with CML CD34 þ cells). Normal CD34 þ cells migrated in response to LPA but no significant effect was seen with CML CD34 þ cells. However, the combination of LPA (2% increase above background) and SDF-1 (an 11% increase above background) generated an enhanced migratory response when the two agonists were used in combination (a 23% increase). The addition of imatinib had a significant effect on CML CD34 þ cell migratory responses to SDF-1 but not to LPA. When the two agents were combined there was no change in the response in the presence of imatinib. Thus, SDF-1 responses appear to be predominantly affected by imatinib. The combination of SDF-1 and LPA demonstrated that CML progenitor cells can undergo migratory responses that are not significantly different from that which is observed in normal CD34 þ cells in the presence of appropriate agonists. The release of CML CD34 þ cells to display a more robust migratory response to SDF-1 by imatinib may be associated with the ability to generate PtdIns(3,4,5)P 3 above CML cell background levels, although this is plainly not so for LPA responses. Nonetheless, when combined with SDF-1, LPA elicits a potentiating effect on cellular transwell migration in nonimatininb-treated CML CD34 þ cells.
We conclude that normal signalling responses in the PI3K pathway are suspended in the presence of the active BCR/ABL. Therefore, discordant regulation of any biological response that requires, the usually exquisite, regulation of PtdIns(3,4,5)P 3 will be apparent in CML cells. As the evidence increases for acquired resistance to imatinib in the treatment of CML the potential value of combining drugs in the treatment of this disease becomes apparent. The pivotal role of PI3K in survival, proliferation and motility responses that are all dysfunctional in CML cells makes this enzyme a potentially useful target for treatment of CML.
We have adapted a novel assay for measuring PtdIns(3,4,5)P 3 to evaluate the levels of this key second messenger in hematopoietic progenitor cells. The value of this technique lies in the fact that often few cells are available for analysis, especially with respect to clinically important cell populations. Studies on the role of PtdIns(3,4,5)P 3 in signal/response coupling in primary stem and progenitor cells will be significantly enhanced using these new reagents and we are in a position to develop a far greater understanding of the role of PtdIns(3,4,5)P 3 in leukemogenesis. 
Figure 3
The effect of LPA or SDF-1 on transwell migration of normal and CML CD34 þ cells. The effects of SDF-1 and LPA on migration of CD34 þ cells were assessed in Boyden chamber assay. Both normal and CML CD34 þ cells were pretreated with imatinib (1 mM) or vehicle control for 16 h prior to the assay. SDF-1 and LPA were added to the bottom wells at concentrations previously shown to give optimal effects on cell migration, 100 ng/ml and 1 mg/ml, respectively. Results shown are the mean7s.e.m. of at least four experiments.
